Subscribe- Air pollutants mediate effects on heart health through inflammation and thrombosis
May 17, 2012 17:15 EDT - Statins benefit those at much lower CV risk
May 16, 2012 18:30 EDT - Azithromycin may up chance of sudden cardiac death
May 16, 2012 17:00 EDT - So long, Plavix, what a ride! Clopidogrel patent expires
May 16, 2012 14:45 EDT - COMFORTABLE-AMI: Bioerodable polymer DES trumps bare metal in STEMI
May 16, 2012 10:50 EDT
MASS-PAC Registry
Just a short blurb here on the continued issue of stent selection.
Though encouraging that this study looked at 67 different propensity matched variables along with Mortality,myocardial infarction and TVR at 3 years in the subgroup of diabetics, classically the toughest audience of all, and found decreased incidences of all the primary endpoints with DES vs. BMS, this wasn't the real story. The real story is that these patients could even be studied at all, and in most places, their data would just be relegated to the patient's medical record and taken deep into some warehouse for storage.
Since this is a registry and not a randomized trial, these patients come to us through inherent selection bias. Someone already determined which patients could safely get a DES and gave it to them. But of those who passed the necessary screening of obvious bleeding, upcoming surgery, compliance issues, etc. etc. in order to get a DES, this study suggests they will bode well.
Our hats are off to the State of Massachusetts for their required reporting of ALL PCI DATA. We could definitely take a lesson from them, and perhaps we should just all follow their example without having to be made to.
Melissa
"Consent the stent" campaign--long overdue!
at 10:05 PM, EDT by Melissa
Hospital interest rates: Taking the family farm
at 08:22 PM, EDT by Melissa
Dr Dean Ornish with manna for the masses
at 10:05 AM, EDT by Melissa
Physicians remember: Mainstream-medicine haters are people too
at 12:37 PM, EDT by Melissa
All natural? $15 billion worth sold annually
at 12:36 AM, EDT by Melissa
Comments
M2S, Inc. has a very robust registry offering that in addition to a clinical pathway for physicians treating AAA and TAA also provides patient outcomes, device performance and physician practice data. 65% of all AAA/TAA procedures in the U.S. are evaluated using M2S providing the largest population of patients available for deeper clinical research. Registries are available and tragically under utilized which is limiting the improvement of patient care to that small population of physicians with a truly altruistic approach.
Meridith
Thanks Meredith for the information. We need more registries AND more RCT's. I hope important discussions and comments such as these will drive change.
Melissa